Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333

Oxygen sensing by HIF hydroxylases

Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068

Hypoxia signalling in cancer and approaches to enforce tumour regression

Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676

Erythropoietin: structure, control of production, and function

JELKMANN, W. E. B. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.2.449 · Cited by 1,167

Chronic Hypoxia and Tubulointerstitial Injury

Nangaku, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070757 · Cited by 1,146

Widespread, hypoxia‐inducible expression of HIF‐2α in distinct cell populations of different organs

Wiesener, M. S., Jürgensen, J. S., Rosenberger, C., Scholze, C. K., Hörstrup, J. H., Warnecke, C., Mandriota, S. J., Bechmann, I., Frei, U. A., Pugh, C. W., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0445fje · Cited by 767

Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor

Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

Ang, S. O., Chen, H., Hirota, K., Gordeuk, V. R., Jelinek, J., Guan, Y., Liu, E., Sergueeva, A. I., Miasnikova, G. Y., Mole, D., et al. (2002) · Nature Genetics · doi:10.1038/ng1019 · Cited by 510

Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells

Warnecke, C., Zaborowska, Z., Kurreck, J., Erdmann, V. A., Frei, U. A., Wiesener, M. S., & Eckardt, K. (2004) · The FASEB Journal · doi:10.1096/fj.04-1640fje · Cited by 404

Identification of the renal erythropoietin-producing cells using transgenic mice

Maxwell, P. H., Osmond, M. K., Pugh, C. W., Heryet, A. R., Nicholls, L. G., Tan, C. C., Doe, B., Ferguson, D. J. P., Johnson, M. H., & Ratcliffe, P. J. (1993) · Kidney International · doi:10.1038/ki.1993.362 · Cited by 388

Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations

Sackeyfio, A., Lópes, R. D., Kovesdy, C. P., Cases, A., Mallett, S. A., Ballew, N., Keeley, T., García-Horton, V., Ayyagari, R., Camejo, R. R., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad298 · Cited by 16

Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)

Drüeke, T. B. (2018) · Renal Replacement Therapy · doi:10.1186/s41100-018-0187-2 · Cited by 16

Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients

Hahn, D., Esezobor, C. I., Elserafy, N. A., Webster, A. C., & Hodson, E. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011690.pub2 · Cited by 16

Mechanism of and Therapy for Kidney Fibrosis

Kuma, A., Tamura, M., & Otsuji, Y. (2016) · Journal of UOEH · doi:10.7888/juoeh.38.25 · Cited by 16

Current and future chemical therapies for treating anaemia in chronic kidney disease

Locatelli, F., Vecchio, L. D., & Luise, M. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1323872 · Cited by 16

Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide

Hofmann, M., & Valliant (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44944 · Cited by 17

Myeloid HIF-1 attenuates the progression of renal fibrosis in murine obstructive nephropathy

Tateishi, Y., Osada‐Oka, M., Tanaka, M., Shiota, M., Izumi, Y., Ishimura, E., Motoyama, K., Inaba, M., & Miura, K. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.011 · Cited by 15

The Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and Disease

Townley-Tilson, W. H. D., Pi, X., & Xie, L. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/676893 · Cited by 15

Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model

Heim, C., Bernhardt, W., Jalilova, S., Wang, Z., Motsch, B., Ramsperger-Gleixner, M., Burzlaff, N. I., Weyand, M., Eckardt, K., & Ensminger, S. M. (2016) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivv352 · Cited by 15

Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers

Shinfuku, A., Shimazaki, T., Fujiwara, M., Sato, F., Watase, H., Numazaki, T., Kawakita, Y., Mutoh, M., Yamasaki, H., Takayama, N., et al. (2018) · American Journal of Nephrology · doi:10.1159/000492181 · Cited by 15

An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

Wilson, P. D., Hutchings, A., Jeans, A., & Macdougall, I. C. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.731458 · Cited by 15

Computational Repositioning and Experimental Validation of Approved Drugs for HIF-Prolyl Hydroxylase Inhibition

Teli, M. K., & Rajanikant, G. K. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400254a · Cited by 15

Implications of Oxygen Homeostasis for Tumor Biology and Treatment

Garvalov, B. K., & Acker, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-7678-9_12 · Cited by 17

Research progress of hypoxia-inducible factor-1α and zinc in the mechanism of diabetic kidney disease

Qin, W., Nie, P., Hui, X., Chen, F., Hu, X., Shi, W., Luo, M., & Li, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1537749 · Cited by 14

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis

Zhang, L., Hou, J., Li, J., Su, S., & Xue, S. (2021) · Aging · doi:10.18632/aging.203143 · Cited by 14

Anemia Treatment, Hemoglobin Variability, and Clinical Events in Patients With Nondialysis-Dependent CKD in Japan

Kuragano, T., Okami, S., Tanaka‐Mizuno, S., Uenaka, H., Kimura, T., Ishida, Y., Yoshikawa‐Ryan, K., James, G., & Hayasaki, T. (2023) · Kidney360 · doi:10.34067/kid.0000000000000204 · Cited by 15

Nothing Iffy about HIF in the Hypothalamus

Virtue, S., & Vidal‐Puig, A. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001116 · Cited by 15

Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials

Higashijima, Y., Tanaka, T., & Nangaku, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.796358 · Cited by 14

Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia

Goi, T., Nakajima, T., Komatsu, Y., Kawata, A., Yamakoshi, S., Okada, O., Sugahara, M., Umeda, A., Takada, Y. K., Murakami, J., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00108 · Cited by 14

The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction

Nakai, T., Saigusa, D., Kato, K., Fukuuchi, T., Koshiba, S., Yamamoto, M. P., & Suzuki, N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122641 · Cited by 15

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Davis–Ajami, M. L., Wu, J., Downton, K. D., Ludeman, E. M., & Noxon, V. (2014) · Biologics · doi:10.2147/btt.s27578 · Cited by 13

Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected Liver Cell Phenotype

Alchera, E., Imarisio, C., Mandili, G., Merlin, S., Chandrashekar, B. R., Novelli, F., Follenzi, A., & Carini, R. (2015) · BioMed Research International · doi:10.1155/2015/286746 · Cited by 13

The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A

Ike, T., Doi, S., Nakashima, A., Sasaki, K., Ishiuchi, N., Asano, T., & Masaki, T. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00083.2022 · Cited by 13

Erythropoietin in anemia of unknown etiology: A systematic review and meta-analysis

Sriram, S., Xenocostas, A., & Lazo‐Langner, A. (2016) · Hematology · doi:10.1080/10245332.2015.1101972 · Cited by 13

Emerging drugs for the treatment of kidney disease-induced anemia

Małyszko, J., & Małyszko, J. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220537 · Cited by 14

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat

Akizawa, T., Tanaka‐Amino, K., Otsuka, T., & Yamaguchi, Y. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02225-w · Cited by 13

Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy

Wu, Y., Wang, N., Lei, Y., Hu, T., You, Q., & Zhang, X. (2016) · MedChemComm · doi:10.1039/c6md00240d · Cited by 13

Targeting Purinergic Signaling for Perioperative Organ Protection

Eltzschig, H. K. (2013) · Anesthesiology · doi:10.1097/aln.0b013e3182874686 · Cited by 12

Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

Ribeiro, S., Garrido, P., Fernandes, J. C., Vala, H., Rocha‐Pereira, P., Costa, E. M., Belo, L., Reis, F., & Santos‐Silva, A. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12541 · Cited by 12

Minimum Alveolar Concentration-Awake of Sevoflurane Is Decreased in Patients With End-Stage Renal Disease

Wu, Y., Jin, S., Zhang, L., Cheng, J., Hu, X., Chen, H., & Zhang, Y. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003676 · Cited by 12

Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: “Can the Promise Be Kept?”

Crugliano, G., Serra, R., Ielapi, N., Battaglia, Y., Coppolino, G., Bolignano, D., Bracale, U. M., Pisani, A., Faga, T., Michael, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212590 · Cited by 12

Disturbance of Hypoxia Response and Its Implications in Kidney Diseases

Li, Z., Wang, B., Wen, Y., Wu, Q., Lv, L., & Liu, B. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0271 · Cited by 11

Does anything work for anaemia in myelofibrosis?

Birgegård, G. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.07.011 · Cited by 10

Hypoxia-inducible factor-prolyl hydroxylase inhibitors in treatment of anemia with chronic disease

Li, Z., Shen, L., Tu, Y., Lü, S., & Liu, B.-C. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003470 · Cited by 10

Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics

Chertow, G. M., Pérgola, P. E., Agarwal, R., Block, G. A., Farag, Y. M. K., Jardine, A. G., Koury, M. J., Luo, W. F., Khawaja, Z., Lewis, E. F., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.068 · Cited by 10

Functional Significance of Erythrocytes

JELKMANN, W. E. B. (2012) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781848166219_0001 · Cited by 10

Anemia in chronic kidney disease patients

Somvanshi, S., Khan, N. Z., & Ahmad, M. (2012) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2012.06.003 · Cited by 9

Renal anemia: from relative insufficiency of EPO to imbalance of erythropoiesis and eryptosis

Yuan, M., Chen, X., Ou, R., Luo, R., Fan, W., Wang, X., & Guo, Z. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04146-x · Cited by 8

Subcellular Energetics and Metabolism: Potential Therapeutic Applications

Thiele, R. H. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001865 · Cited by 8

Anemia Of Chronic Renal Disease

Shaikh, H. G., & Aeddula, N. R. (2019) · StatPearls · Cited by 8

WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease

Lee, W., Chiu, C.-H., Chu, T., & Chien, Y.-S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.876723 · Cited by 8

Molecular oxygen sensing: implications for visceral surgery

Kiss, J., Kirchberg, J., & Schneider, M. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0930-z · Cited by 8

Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?

Locatelli, F., & Vecchio, L. D. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz031 · Cited by 8

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?

Grzeszczak, W., Szczyra, D., & Śnit, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041612 · Cited by 8

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis

Wu, M., Zang, C., Ma, F., Chen, B., Liu, J., & Xu, Z. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02263-4 · Cited by 7

Poor recognition and undertreatment of anemia in patients with chronic kidney disease managed in primary care

Xu, Y., Evans, M., Mazhar, F., Ärnlöv, J., Cockburn, E., Barany, P. F., & Carrero, J. J. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13702 · Cited by 7

The effect of HIF stabilizer on distraction osteogenesis

Özdel, A., Sarısözen, B., Yalçınkaya, U., & Demirağ, B. (2015) · Acta Orthopaedica et Traumatologica Turcica · doi:10.3944/aott.2015.14.0006 · Cited by 6

Seeking for a way to revive erythropoietin production in chronic kidney disease

Chang, Y., Pan, S., & Lin, S. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.04.005 · Cited by 6

Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge

Portolés, J. M., Oberbauer, R. W., Eisenga, M. F., Cases, A., Małyszko, J., Choukroun, G. J., Crespo, M., Eckardt, K., & Minutolo, R. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf252 · Cited by 5

Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia

Fukuda, T., Kuribayashi, T., Takano, R., Sasaki, K., Tsuji, T., Niitsu, Y., Ishii, K. J., Hashimoto, M., Baba, D., Ito, S., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129799 · Cited by 5

Endoplasmic Reticulum: The Master Regulator of Stress Responses in Glomerular Diseases

Inagi, R. (2011) · InTech eBooks · doi:10.5772/22098 · Cited by 5

Nuevas expectativas en el tratamiento de la anemia en la enfermedad renal crónica

López–Gómez, J. M., Abad, S., & Vega, A. (2016) · Nefrología · doi:10.1016/j.nefro.2016.03.006 · Cited by 5

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease

Natale, P., Palmer, S. C., Tong, A., Ruospo, M., Hodson, E. M., Cooper, T. E., Hahn, D., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013751 · Cited by 5

Scaffold hopping strategy to derive 4‐hydroxy‐1‐alkyl‐2‐oxo ‐1, 2‐dihydrothieno [2,3‐b:4,5‐b′] dipyridine‐3‐carbonylglycine derivatives as a novel hypoxia‐inducible factor prolyl hydroxylase domain inhibitor for the potential treatment of chronic kidney disease anemia

Park, G. Y., Park, C., Lee, S. K., Im, C. Y., Kim, S., Hwang, H.-J., Lee, J., Lee, T., Hong, Y. R., & Song, M. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12652 · Cited by 5

Hypoxia Signaling in the Cell Type-Specific Regulation of Erythropoietin Production Throughout Mammalian Development

Suzuki, N., Nakai, T., Iwamura, Y., & Kato, K. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2522720 · Cited by 4

Prolyl Hydroxylase Inhibitor-Mediated HIF Activation Drives Transcriptional Reprogramming in Retinal Pigment Epithelium: Relevance to Chronic Kidney Disease

Gáll, T., Pethő, D., Nagy, A., Póliska, S., Balla, G., & Balla, J. (2025) · Cells · doi:10.3390/cells14141121 · Cited by 5

Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease

Wyatt, C. M., & Drüeke, T. B. (2020) · Kidney International · doi:10.1016/j.kint.2019.12.005 · Cited by 4

Iron indices and hemogram in renal anemia and the improvement with Tribulus terrestris green-formulated silver nanoparticles applied on rat model

Wu, X., Shi, J., Dai, Y., Tang, W., Cao, H., & Chen, J. (2024) · Open Chemistry · doi:10.1515/chem-2023-0212 · Cited by 4

Hydrophobic constituents of Polygonum multiflorum roots promote renal erythropoietin expression in healthy mice

Shirako, S., Ulfa, S. M., Nishidono, Y., Dwijayanti, D. R., Okuyama, T., Nakatake, R., Tanaka, K., Ikeya, Y., & Nishizawa, M. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01737-3 · Cited by 4

Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string

Tai, G., Xia, F., Chen, C. Y.-H., Pereira, A. I., Pirhalla, J. L., Miao, X., Young, G. C., Beaumont, C., & Chen, L. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1145 · Cited by 4

Why not the liver instead of the kidney?

Fandrey, J. (2012) · Blood · doi:10.1182/blood-2012-06-433201 · Cited by 4

The Isoquinolone Derived Prolyl Hydroxylase Inhibitor ICA Is a Potent Substrate of the Organic Anion Transporters 1 and 3

Schulz, K., Hagos, Y., Burckhardt, G., Schley, G., Burzlaff, N. I., Willam, C., & Burckhardt, B. C. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000442531 · Cited by 4

Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?

Locatelli, F., & Vecchio, L. D. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000432 · Cited by 4

New expectations in the treatment of anemia in chronic kidney disease

López–Gómez, J. M., Abad, S., & Vega, A. (2016) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2016.07.002 · Cited by 4

Explore the effect of HIF-PHI on blood pressure variation rate and anemia efficacy in maintenance hemodialysis patients

Yang, Y., Wang, Y., Qi, Y., Fu, Z., Hu, Y., Wan, J., Shi, X.-T., Huang, J., He, H., Chen, Q., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-024-03928-w · Cited by 3

Hypoxia-inducible factor prolyl 4-hydroxylase-2 in Tibetan high-altitude adaptation, extramedullary erythropoiesis and skeletal muscle ischemia

Myllymäki, M. (2016) · Cited by 3

Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms

Merz, A. M. A., & Platzbecker, U. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.11.004 · Cited by 3

Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care

Schiller, B. M., & Besarab, A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.588202 · Cited by 3

Special Populations with Anemia: Anemia in the Pediatric Patient

Kalpatthi, R. V., Atkinson, M. A., & Warady, B. A. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7360-6_12 · Cited by 3

Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy

Votava, J. A., Reese, S. R., Deck, K. M., Nizzi, C. P., Anderson, S. A., Djamali, A., & Eisenstein, R. S. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00537.2020 · Cited by 3

A Fluorescent Benzo[g]isoquinoline‐Based HIF Prolyl Hydroxylase Inhibitor for Cellular Imaging

Mayer, M., Fey, K., Heinze, E., Wick, C. R., Abboud, M. I., Yeh, T., Tumber, A., Orth, N., Schley, G., Buchholz, B., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800483 · Cited by 3

Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients

Kanda, R., Kubo, A., Seki, T., Urita, A., Sekiuchi, M., & Tomino, Y. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13717 · Cited by 3

Treatment of anemia in chronic kidney disease: known, unknown, and both

Foley, R. N. (2011) · Journal of Blood Medicine · doi:10.2147/jbm.s13066 · Cited by 3

Mast Cells and Intestinal Injury

Grenz, A., & Eltzschig, H. K. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e318283cc70 · Cited by 3

Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review

Haase, V. H., Costa, N. A., & Koury, M. J. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.017 · Cited by 2

New alternatives in anemia treatment: biosimilars and HIF stabilizers.

Krishnan, M., & Nissenson, A. R. (2014) · PubMed · Cited by 2

The hypoxia-inducible factor prolyl hydroxylase inhibitor FG4592 promotes natriuresis through upregulation of COX2 in the renal medulla

Guan, N., Zhang, M., Gong, W.-Y., Mao, X., Yang, S., & Hao, C. (2022) · Hypertension Research · doi:10.1038/s41440-022-00889-1 · Cited by 2

Toward evaluation of multiresolution cortical thickness estimation with FreeSurfer, MaCRUISE, and BrainSuite

Nian, R., Gao, M., Zhang, S., Yu, J., Gholipour, A., Kong, S., Wang, R., Sui, Y., Velasco‐Annis, C., Tomas-Fernandez, X., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac401 · Cited by 2

Erythropoietin gene doping: facts and fictions

JELKMANN, W. E. B., & JELKMANN, W. E. B. (2012) · German Journal of Exercise and Sport Research · doi:10.1007/s12662-012-0268-2 · Cited by 2

Current Quandaries in Cancer-Associated Anemia

Gilreath, J. A., & Rodgers, G. M. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0104 · Cited by 2

New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?

Ryšavá, R. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.092 · Cited by 1

Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor

Fukuda, T., Nishi, T., Ishiyama, T., Kitazawa, R., Ishii, K. J., Takahashi, S., Kawabata, Y., Yamaguchi, K., Baba, D., Ito, S., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130476 · Cited by 1

Purinergic Signaling, HIF, and ROS Interactions in Myocardial I/R Injury: Therapeutic Potential and Future Prospective

Singh, M. K., Yun, H. R., Ranbhise, J. S., Han, S., Seo, H., Yeo, S. G., Quan, F., Kim, S. S., & Kang, I. (2026) · Cells · doi:10.3390/cells15080682 · Cited by 2

Erythropoietin and Chronic Kidney Disease Alter Hepatic Expression of Cytochrome P450 Enzymes and Drug Transport Proteins

Feere, D. A. (2014) · Scholarship@Western (Western University) · Cited by 1

Benefits and risks of erythrocyte-stimulating agents

Katagiri, D. (2014) · World Journal of Clinical Urology · doi:10.5410/wjcu.v3.i3.258 · Cited by 1

The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia

TANAKA, M., Ikuma, M., Asakura, W., & Fujiwara, Y. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2275 · Cited by 1

Full Blood Count, Urea and Electrolytes, Bicarbonate, Bone Profile

Rayner, H. C., Thomas, M., & Milford, D. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23458-8_13 · Cited by 1

The HIF System Response to ESA Therapy in CKD‐Anemia

Ribeiro, S., Belo, L., Reis, F., & Santos‐Silva, A. (2017) · InTech eBooks · doi:10.5772/65646 · Cited by 1

Anemia in Chronic Kidney Disease

Berns, J. S., Wong, T. C., & Dawson, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00009-4 · Cited by 1

Erythropoietin levels after bilateral nephrectomy for renal cell carcinoma; a case report

Sekiguchi, K., Abe, T., Matsuura, T., Moriwaka, M., Takahashi, K., & Obara, W. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02407-0 · Cited by 1

MIR193BHG: a novel hypoxia-inducible long noncoding RNA involved in the fine-tuning of cholesterol metabolism

Wu, X. (2016) · IUScholarWorks (Indiana University) · doi:10.7912/c2s89r · Cited by 1

Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients

Hahn, D., Esezobor, C. I., Elserafy, N. A., Webster, A. C., & Hodson, E. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011690 · Cited by 1

Emerging Therapies for Chronic Kidney Disease

Roy‐Chaudhury, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00064-0

Hypoxia-Associated Regulation within Implantation Sites

Alahari, S., Caniggia, I., & Caniggia, I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394445-0.00018-7

Studies on treatment of renal anemia in patients on chronic hemodialysis

Stefánsson, B. V. (2011) · Skemman

Anemia and response to erythropoietin in the cardiorenal syndrome

van der Putten, K. (2011) · Utrecht University Repository (Utrecht University)

Comparison of Hematological Parameters of Uremic Patients with β-Thalassemia Receiving Peritoneal Dialysis and Hemodialysis

Wang, S., Wu, T.-T., Yang, K.-L., Ju, W.-C., Liang, C.-C., Chang, C., & Huang, C. (2012)

Hypoxic Response in Senescent Brain Is Impaired: Possible Contribution to Neurodegeneration

Rabie, T. (2013) · Springer eBooks · doi:10.1007/978-94-007-5958-9_15

1. Future Perspectives of Kidney Disease

Nangaku, M. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.1166

Renal Erythropoietin-producing Cells in Renal Diseases

Nakata, H., & Yanagita, M. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.160

Upregulation of Endogenous Erythropoietin (EPO) in Healthy Subjects by Inhibition of Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase.

Urquilla, P. R., Fong, A., Oksanen, S., Leigh, S. D., Turtle, E. D., Flippin, L. A., Brenner, M., Muthukrishnan, E., Fourney, P., Lin, A., et al. (2004) · Blood · doi:10.1182/blood.v104.11.174.174 · Cited by 19

The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction

Nakai, T., Saigusa, D., Kato, K., Fukuuchi, T., Koshiba, S., Yamamoto, M. P., & Suzuki, N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122641 · Cited by 15

Stabilizing HIF to Ameliorate Anemia

Voit, R. A., & Sankaran, V. G. (2020) · Cell · doi:10.1016/j.cell.2019.12.010 · Cited by 58

Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,

Querbes, W., Bogorad, R. L., Moslehi, J. J., Akinc, A., Wong, J., Zurenko, C. S., Qin, J., Hettinger, J. L., Kuchimanchi, S., Charissé, K., et al. (2011) · Blood · doi:10.1182/blood.v118.21.3161.3161 · Cited by 1

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

Ariazi, J. L., Duffy, K. J., Adams, D. F., Fitch, D. M., Luo, L., Pappalardi, M. B., Biju, M. P., DiFilippo, E. H., Shaw, T., Wiggall, K., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242503 · Cited by 94